01099 SINOPHARM
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 1.41X | Oper Margin | 2.8% |
|---|---|---|---|
| LT Debt/Equity | 7.3% | Net Margin | 1.2% |
| Total Debt/Equity | 84.5% | Return on Equity | 8.5% |
| Price/Book | 0.70X | Return on Assets | 1.8% |
| (HKD 20.920) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 7,964.34 | 7,497.34 | 9,979.05 | 9,558.96 | 9,489.60 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +6.2 | -24.9 | +4.4 | +0.7 | +11.3 |
| Earnings Per Share (HKD) | 2.552 | 2.403 | 3.198 | 3.063 | 3.041 |
| Earnings Per Share Growth (%) | +6.2 | -24.9 | +4.4 | +0.7 | +10.9 |
| Dividend Per Share (HKD) | 0.768 | 0.739 | 0.956 | 0.900 | 0.872 |
| P/E* (X) | 8.20 | 8.71 | 6.54 | 6.83 | 6.88 |
| Yield (%) | 3.67 | 3.53 | 4.57 | 4.30 | 4.17 |
| Dividend Share (%) | 30.09 | 30.76 | 29.90 | 29.38 | 28.68 |
| Book NAV (HKD) | 29.945 | 26.883 | 26.342 | 24.456 | 24.255 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 575,168 | 584,508 | -1.6 | 596,570 |
| Operating Result | 13,535 | 12,712 | +6.5 | 17,892 |
| Associates | 1,233 | 1,199 | +2.8 | 1,107 |
| Profit Before Taxation | 14,800 | 14,001 | +5.7 | 19,512 |
| Taxation | 3,965 | 3,577 | +10.8 | 4,502 |
| Profit /( Loss) After Taxation | 10,834 | 10,424 | +3.9 | 15,010 |
| Minority Interests | 3,679 | 3,374 | +9.0 | 5,956 |
| Net Profit | 7,155 | 7,050 | +1.5 | 9,054 |
| Earnings Per Share () | 2.5522 | 2.4025 | +6.2 | 3.1977 |
| Dividend Per Share () | 0.7680 | 0.7390 | +3.9 | 0.9560 |
| Announcement Date | 2026-03-23 | 2025-03-24 | NA | 2024-03-25 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
